RxDoctor Payments Data

Jorge Gardyn, MD

Internal Medicine · Amityville, NYNPI 1629060983

Payments from drug & device makers

$3,620in general payments, 2019–2025

Across 97 payments — averaging $37.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$872
  • Amgen$861
  • Genentech USA, Inc.$202
  • Pfizer$199
  • Novo Nordisk$187
  • AbbVie$166
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,620 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$144,510
Medicare patients
180
Services billed
2,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide77$86,198
JanuviaSitagliptin Phosphate19$23,762
TrulicityDulaglutide18$23,311
XareltoRivaroxaban20$22,999
OzempicSemaglutide16$18,748
EliquisApixaban13$15,210
VascepaIcosapent Ethyl12$3,608
Levothyroxine Sodium151$2,500
Metoprolol Succinate146$2,173
Atorvastatin Calcium246$2,101
SynthroidLevothyroxine Sodium16$1,482
PaxlovidNirmatrelvir/Ritonavir14$1,429
Pregabalin19$1,039
Pantoprazole Sodium69$876
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide62$861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$129$109,50995 claims
MerckJanuvia$43$23,76219 claims
Johnson & JohnsonXarelto$135$22,99920 claims
Novo NordiskOzempic$187$18,74816 claims
PfizerEliquis, Paxlovid$199$16,63927 claims
AbbVieSynthroid$166$1,48216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Amityville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →